China Pharma Link is the bridge. Monthly deal intelligence, plus direct access to Chinese companies actively seeking Western partnerships.
The Chinese pharma market has leading companies in the development of biosimilars, innovative medicines, generics, and new medical devices. The vast majority of Western BD teams have never heard of them, or have limited access.
The Chinese pharmaceutical landscape is moving fast and these companies are actively looking for Western partners. Western BD teams are trying to track it all from thousands of miles away, without the language, the relationships, or the regulatory context to do it effectively. China Pharma Link is how you close that gap.
China Pharma Link was built to solve that. Every month, subscribers get the cross-border deals worth knowing about and direct access to carefully selected Chinese companies actively seeking Western partners. Not just intelligence. Real deal flow.
Monthly briefings on the most significant cross-border deals involving Chinese pharma companies — licensing, co-development, supply agreements — with analysis on what each deal signals for the market.
Direct access to a curated network of Chinese manufacturers who are deal-ready and have been qualified by our team. No cold outreach. No unvetted directories.
Founded by operators with 15 years of Western BD experience and 30 years on the ground in China. We understand what both sides need to make a deal work.
The China Pharma Brief. Monthly intelligence on deals and direct access to Chinese companies seeking Western partners.
Subscribe →